Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Progressive Sarcoidosis
NCT00311246Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Apr 2006
- Primary completion
- May 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in pulmonary sarcoidosis, sponsored by University of Chicago. Primary endpoint: Forced Vital Capacity at 24 weeks. Started Apr 2006; status: terminated.
02
Drugs
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT00311246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311246.